Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Forma Therapeutics, Inc.
Modality
Small molecule
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03684811CT.gov A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chondrosarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Olutasidenib (this asset) | Forma Therapeutics, Inc. | P1/2 | CCC · 52 |
| Ivosidenib | Memorial Sloan Kettering Cancer Center | P2 | B |
| Talfirastide | Wake Forest University Health Sciences | P2 | CCC |
| Azacitidine | IGM Biosciences, Inc. | P1/2 | CCC |
| Cis-Diamminedichloroplatinum Ii | Eli Lilly and Company | P1/2 | CCC |
| Adapt-001 | EpicentRx, Inc. | P2 | CCC |
| Atezolizumab | National Cancer Institute (NCI) | P2 | CCC |
| Nivolumab | Forma Therapeutics, Inc. | P1/2 | CCC |
| Vismodegib | National Cancer Institute (NCI) | P1/2 | CCC |
+14 more in the Chondrosarcoma cohort
Other indications for Olutasidenib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Glioma | — | P4 | BBB · 72 |
| Acute Myeloid Leukemia | — | P4 | BB · 66 |
| Myelodysplastic Syndrome | — | P2 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Olutasidenib in Chondrosarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/olutasidenib-chondrosarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →